- Author(s): Élise Noël-Savina, Renaud Descourt
, CHU de Brest, hôpital Morvan, service d’oncologie thoracique, 5, avenue Foch, 29200 Brest, France
- Key words: granulocyte colony-stimulating factor, ARDS, pneumonia, neutropenia, recovery aplasia, pulmonary toxicity
- Page(s) : 211-7
- DOI : 10.1684/bdc.2011.1534
- Published in: 2012
Granulocyte colony-stimulating factor (G-CSF) are frequently used in oncology and haematology practice. Respiratory disturbance has been reported during administration of G-CSF. G-CSF may induce pulmonary toxicity but this fact remains an open debate because of its frequent association with other drugs. The action of these treatments could explain a part of the pulmonary events but not completely. The specific pulmonary effect of the G-CSF is probably underestimated. Most of these pulmonary events occur in association with other risk factors, mainly when a pneumonia occurs during the neutropenia. However, G-CSF are recommended in febrile neutropenia.